Vertex achieved all of its clinical, research and financial objectives in 2005. In particular, we increased our financial strength as we advanced potentially transformational compounds targeting hepatitis C virus (HCV), rheumatoid arthritis and cystic fibrosis. Our performance last year has positioned us to build momentum in 2006.
— Joshua Boger
ResearchStrength